Cystic adenomatoid malformation of the lung: Review of genetics, prenatal diagnosis, and in utero treatment

R. Douglas Wilson, Holly L. Hedrick, Kenneth W. Liechty, Alan W. Flake, Mark P. Johnson, Michael Bebbington, N. Scott Adzick

Research output: Contribution to journalReview articlepeer-review

142 Scopus citations

Abstract

Prenatal identification of lung abnormalities has increased with prenatal surveillance. Treatment usually requires serial ultrasound observation but in rare situations in utero therapy may be required for fetal survival. We review the genetics, prenatal evaluation, and treatment of lung abnormalities with congenital cystic adenomatoid malformation (CCAM). Other lung lesions, bronchopulmonary sequestration (BPS), hybrid lesions involving both malformations, congenital lobar emphysema (CLE), are briefly included as differential diagnosis options. Outcome of fetuses identified to have CCAM lung abnormalities resulting in fetal hydrops and having in utero therapy (thoracoamniotic shunting, fetal thoracotomy, EXIT delivery) are discussed. In the appropriate situation, this maternal fetal surgery approach for CCAM is life-saving for the affected fetus with acceptable maternal morbidity risks in the present and future pregnancies.

Original languageEnglish
Pages (from-to)151-155
Number of pages5
JournalAmerican Journal of Medical Genetics
Volume140 A
Issue number2
DOIs
StatePublished - Jan 15 2006

Keywords

  • Cystic adenomatoid malformation of the lung
  • EXIT
  • In utero treatment
  • Prenatal diagnosis
  • Thoracoamniotic shunting

Fingerprint

Dive into the research topics of 'Cystic adenomatoid malformation of the lung: Review of genetics, prenatal diagnosis, and in utero treatment'. Together they form a unique fingerprint.

Cite this